Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[CHEK1 expression and inhibitors in TP53 mutant cancer].

Magyar onkologia - 9 Dec 2019

Õsz Ágnes, Aszódi Boglárka, Vajda Réka, Keserû Miklós György, Moll Herwig P, Casanova Emilio, Gyõrffy Balázs

Abstract excerpt

The most frequently mutated gene in human tumors is TP53 and its mutation significantly deteriorates patients' survival. However, to date no targeted therapy is established for TP53 mutated tumors. Here, our aim was to identify druggable kinases with higher expression in TP53 mutated tumors, as well as relate these to altered prognosis. We also aimed to validate a target gene in TP53 wild type and mutant isogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to Lung Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Survival Analysis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 31821389

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

[CHEK1 expression and inhibitors in TP53 mutant cancer].PMID 31821389Read ↗

CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells.Semantic proximity Read ↗

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agentsSemantic proximity Read ↗

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.Semantic proximity Read ↗

[p53 mutations as prognostic factors of hepatocellular carcinomas].Semantic proximity Read ↗

Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapiesSemantic proximity Read ↗

[p53 mutations and their role in tumorigenesis].Semantic proximity Read ↗

Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.Semantic proximity Read ↗

TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 DatabaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.